IOVA Company Profile and Key Details
Iovance Biotherapeutics
Price Chart
Stock Price Today
Iovance Biotherapeutics, Inc. (IOVA) stock surged +1.19%, trading at $3.40 on NASDAQ, up from the previous close of $3.36. The stock opened at $3.37, fluctuating between $3.34 and $3.50 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 30, 2026 | 3.34 | 3.42 | 3.30 | 3.36 | 16.27M |
| Apr 29, 2026 | 3.37 | 3.37 | 3.27 | 3.31 | 8.82M |
| Apr 28, 2026 | 3.43 | 3.50 | 3.33 | 3.38 | 11.27M |
| Apr 27, 2026 | 3.45 | 3.59 | 3.42 | 3.43 | 10.21M |
| Apr 23, 2026 | 3.50 | 3.58 | 3.38 | 3.48 | 15.31M |
| Apr 22, 2026 | 3.75 | 3.81 | 3.40 | 3.53 | 22.1M |
| Apr 21, 2026 | 3.79 | 3.91 | 3.65 | 3.70 | 10.89M |
| Apr 20, 2026 | 3.75 | 3.86 | 3.66 | 3.78 | 9.72M |
| Apr 17, 2026 | 3.93 | 3.97 | 3.85 | 3.86 | 10.6M |
| Apr 16, 2026 | 3.82 | 3.87 | 3.71 | 3.80 | 10.95M |
| Apr 14, 2026 | 3.49 | 3.69 | 3.44 | 3.64 | 13.15M |
| Apr 13, 2026 | 3.69 | 3.81 | 3.42 | 3.46 | 17.85M |
| Apr 10, 2026 | 3.99 | 4.31 | 3.63 | 3.70 | 44.13M |
| Apr 09, 2026 | 3.49 | 4.05 | 3.48 | 4.01 | 26.5M |
| Apr 08, 2026 | 3.46 | 3.50 | 3.25 | 3.47 | 15.41M |
| Apr 07, 2026 | 3.26 | 3.43 | 3.18 | 3.32 | 9.44M |
| Apr 06, 2026 | 3.42 | 3.48 | 3.28 | 3.30 | 9.57M |
| Apr 02, 2026 | 3.34 | 3.51 | 3.32 | 3.43 | 7.47M |
| Apr 01, 2026 | 3.60 | 3.65 | 3.39 | 3.45 | 9.22M |
| Mar 31, 2026 | 3.43 | 3.58 | 3.37 | 3.51 | 10.9M |
Contact Details
About Company
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universit� de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Company Information
| Employees | 838 |
| Beta | 0.74 |
| Sales or Revenue | $1.19M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Vice President of Investor Relations & PR
Mr. Jean-Marc Bellemin M.B.A.
Chief Financial Officer, Principal Accounting Officer & Treasurer
Dr. Raj K. Puri M.D., Ph.D.
Executive Vice President of Regulatory Strategy & Translational Medicine
Ms. Tracy Winton
Senior Vice President of HR
Mr. Madan Jagasia
Executive Vice President of Medical Affairs
Dr. Igor P. Bilinsky
Chief Operating Officer
Mr. Brian Shew M.B.A.
Senior Vice President & Head of Digital and Information Technology
Mr. Howard B. Johnson M.B.A.
Chief Bus. Officer
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Interim Chief Executive Officer, Pres, Gen. Counsel & Corporation Sec.
Mr. James Ziegler M.B.A.
Executive Vice President of Commercial
Dr. Friedrich Graf Finckenstein M.D.
Chief Medical Officer
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep